Evosep Biosystems’ Post

What are the challenges that genomic testing service providers are facing when it comes to Health Technology Assessment models and paths to funding? Our PTA-C/24 expert genomics panel shared their HTA experiences and we captured it on video. Watch the recap or learn for the first time if you missed the congress. Australia's HTA processes were designed over 20 years ago around a one test – one intervention approach. Genetic testing doesn't just predicate treatment, it is a completely new way of thinking about a disease. Our assessment and funding processes need to evolve in recognition of the myriad of impacts and value this technology can provide. We value the privacy of our speakers through a password protection process. It's easy to sign up and join our community! Go to https://lnkd.in/gBqHfeci and fill in the form to receive the password. You'll gain access to all the conference video footage cut into bite-size pieces for easy watching. Listen to this snippet from the PTA-C/24 genomics panel convened by PTA’s Government Affairs and Communications Lead, Madeline O'Donoghue, featuring a range of genomic testing service providers including Professor David Thomas (Omico), Professor Stephen Fox (Peter MacCallum Cancer Centre), and Dr Kym Mina (Genomics Pathologist with private pathology experience). #PTAC24 #genomics #GenomicTesting #cancer #GenomicScreening #diagnostics #HealthCongress #WeArePTA

#WAOJournal: Exploring #biomarkers for #chronic #rhinosinusitis in adult #asthma patients within real-world healthcare settings is crucial for advancing clinical research. Identifying these biomarkers can lead to improved diagnostics, personalized treatment plans, and better patient outcomes. By delving into biological indicators associated with both conditions, healthcare professionals can enhance their understanding of the underlying mechanisms and potential correlations. This research endeavor aims to bridge gaps in current knowledge and provide valuable insights for more targeted interventions. #MedicalResearch #HealthcareInnovation https://buff.ly/3uHCUXl

Recently published on The Lancet Digital Health, this article offers an in-depth focus on Digital Therapeutics' clinical trials and their development into the clinical landscape. The interesting insights are based on a research of more than 400 DTx clinical trials initiated, or expected to be initiated, between 2010 and 2030 including, among the available analyzed data, the trial's duration and the Medical Subject Headings categories (MeSH). As GDMH's mission is to be a global player in the deployment of digital medicine solutions in a constantly challenging medical scenario, this article similarly showcases the challenging opportunities clinicians and researchers have in designing inclusive DTx clinical trials which could provide several options of personalised care to prevent individuals' diseases, managing their therapy's journeys. Click the link below to read the full article 👉 https://lnkd.in/dKxXnM_i  . #togethermovefirst #digitalmedicine #medicalpractice #clinicaltrials

In this Nat Rev Clin Oncol Perspective, Drs Hung-Yang Kuo, Kabir Khan & Robert Kerbel describe the rationale for angio-immunotherapy combinations, summarize the outcomes of completed phase III clinical trials, discuss successes versus failures and the potential factors that account for these differences, and suggest future experimental and clinical initiatives for improving patient outcomes using this treatment strategy. https://lnkd.in/eWa2Z-wm

Our latest blog explores the power of Advanced Diagnostics & CGP to revolutionize patient care with personalized treatments. We discuss the challenges these innovations face and unveil strategies to overcome them, paving the way for a more accessible future of precision medicine. Dive in now! #MarksManHealthcare #BlogPosts #AdvancedDiagnostics #ComprehensiveGenomicProfiling #HealthTechnologies #MarketAccess #PrecisionMedicine

What is Clinical Research and Why is it Important? Clinical research is the foundation of modern medicine. It’s the process by which we test new treatments, interventions, or methods in real-world settings to see if they’re safe and effective. Without clinical research, we wouldn’t have life-saving medications, advanced therapies, or evidence-based healthcare. Why should you care? 1. Patient Outcomes: Clinical research directly improves the quality of patient care. Each study aims to find better treatments or understand diseases more deeply. 2. Innovation in Medicine: New treatments come from clinical trials. What works in the lab must prove its efficacy in human trials before it’s used in clinics. 3. Healthcare Advancements: Every major advancement in healthcare – from vaccines to cancer treatments – started as a clinical trial. By participating in or supporting clinical research, you’re helping shape the future of healthcare. Let’s build a healthier tomorrow, one study at a time! #ClinicalResearch #MedicalResearch #HealthcareInnovation #ResearchMatters #ClinicalTrials #HealthcareAdvancement #MedicalScience #PatientCare #HealthResearch #EvidenceBasedMedicine

Portal Innovations, LLC A.I. in Healthcare Panel discussion with Meesha Dogan, PhD of Cardio Diagnostics Holdings Inc. and Amit Gupta of Cardiosense. Moderated by Steven Lehmann. An important topic featuring science founded in #chicago’s biotech ecosystem. Both companies bring their tech to bear to solve cardiovascular disease—a topic that touches most of us.

In this edition of In The Network, spend a few minutes learning about the beginning of clinical trials, how they work, and how AON supports them. Read the article > https://hubs.li/Q02J4vs90 #InTheNetwork #CancerCare #WeAreAON

New trial! Michael Lim, MD, of Stanford University School of Medicine, leads Alliance A072201 – a phase II trial to compare the effectiveness of anti-lag-3 (relatlinib) and anti-PD-1 blockade (nivolumab) to standard of care lomustine to treat patients with recurrent #glioblastoma after a period of improvement. To learn more, visit https://lnkd.in/ghsjkxNw #NCI #NCTN

In today's rapidly evolving healthcare landscape, Patient-Centered Precision Medicine (PCPM) is revolutionizing how we approach treatment by integrating a multi-omics strategy. This innovative approach tailors medical care to the unique genetic, environmental, and lifestyle factors of each patient, ensuring that treatments are not just effective but also personalized. The significance of PCPM lies in its ability to utilize comprehensive biological data—from genomics to metabolomics—to inform clinical decisions. By understanding the intricate molecular profiles of patients, healthcare providers can predict responses to therapies more accurately, leading to improved outcomes and minimized side effects. This is especially crucial for managing complex diseases like cancer, where individual variations can significantly affect treatment efficacy. As we strive towards a more inclusive healthcare system, embracing PCPM with a multi-omics perspective not only enhances patient care but also aligns with global health goals for equitable access to innovative treatments. Let’s champion this transformative approach that puts patients at the heart of their healthcare journey! #PrecisionMedicine #PatientCenteredCare #MultiOmics #HealthcareInnovation #PersonalizedMedicine #HealthEquity #DataDrivenHealthcare Share Rewrite